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MicroScanStewardship of the dwindling number of effective antibiotics relies on accurate phenotyping. We sought to con-
duct the ﬁrst large-scale, same plate and day comparison of the 3most widely used bacterial analyzers. A total of
11,020 multidrug-resistant clinical isolates corresponding to more than 485,000 data points were used to com-
pare the 3 major identiﬁcation and antibiotic susceptibility testing (AST) platforms. Bacterial suspensions, pre-
pared from a single plate, were simultaneously tested on all platforms in the same laboratory. Discrepancies
were derived fromMIC values using 2014 interpretive guidelines.Molecularmethods andmanualmicrobroth di-
lution were reference standards. Most discrepancies were due to drug–organism–AST platform combination in-
stead of individual factors. MicroScan misidentiﬁed Acinetobacter baumannii (P b 0.001) and underestimated
carbapenem susceptibility in Klebsiella pneumoniae. Vitek-2 and Phoenix had higher discrepancies for blaKPC-
containing Enterobacteriaceae (P b 0.05) and reported false susceptibilities more often. While all platforms per-
formed according to standards, each had strengths and weaknesses for organism identiﬁcation, assaying speciﬁc
drug–organism combinations and inferring carbapenemase production.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Clinicians and infection preventionists rely on accurate laboratory
results to direct therapy and support infection control or antibiotic
stewardship (Bartlett et al., 2013; Boucher et al., 2009; Center for Dis-
ease Control, 2013a; Hoang et al., 2013; Pfeiffer and Beldavs, 2014; Tal-
bot et al., 2006;WHO, 2014). Comparative effectiveness research is key
to quality and cost in healthcare and considered a priority by the Insti-
tute of Medicine and the Agency on Healthcare Research and Quality
(Sox and Greenﬁeld, 2009; Agency for Healthcare Research and Quality,
2012). Furthermore, the College of American Pathologists (CAP) re-
quires laboratories seeking accreditation to conduct comparison studies
when they usemultiple platforms for the same test (i.e., organism iden-
tiﬁcation [ID] and antibiotic susceptibility testing [AST]). Earlier
comparison studies indicated that the Phoenix (BD Diagnostics,
Sparks, MD, USA) had the highest sensitivity for detecting extended-
spectrum β-lactamases (ESBLs) and carbapenemase producers inly those of the authors and not
S. Department of State, the De-
1-301-319-9801.
ielsen).
ss article under the CC BY-NC-ND liceEnterobacteriaceae relative to the Vitek-2 and MicroScan systems
(Wiegand et al., 2007; Woodford et al., 2010). However, those studies
looked at relatively small numbers of locally acquired isolates and relied
on outside reference laboratories when comparing 2 or more
platforms. This limits generalizability and introduces variance such as
changes in inoculum densities, growth conditions, or sample handling
(Bratu et al., 2005; Thomson and Moland, 2001).
To our knowledge, there are no large-scale studies that assessed the
results of the 3 most widely used platforms after simultaneous testing
and included over 200 conﬁrmed carbapenemase producers. Such
data would be useful for baseline accreditation efforts and future
benchmarking.
In our study, the Phoenix, Vitek-2 (bioMerieux, Durham, NC, USA)
and MicroScan (Seimens, Deerﬁeld, IL, USA) platforms were evaluated
for their ability to accurately characterize over 11,000 genetically di-
verse multidrug-resistant organisms (MDROs) including 1323
Acinetobacter baumannii, 547 Klebsiella pneumoniae, 678 Pseudomonas
aeruginosa, 2072 Escherichia coli, and 6400methicillin-resistant Staphy-
lococcus aureus (MRSA) isolates grown on the same plate, with the same
set-up time on each platform by the same accredited laboratory. Fur-
thermore, AST and identiﬁcation discrepancy rates of N200 isolates con-
ﬁrmed to contain blaKPC, blaNDM, blaIMP, or blaVIM were compared to
noncarbapenemase producers. Matrix-assisted laser desorption/nse (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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dilution, and/or the results of the submitting hospital laboratory were
used as reference standards or to resolve discordances.
2. Methods
This study was undertaken as a quality improvement, infection con-
trol initiative authorized by policy memoranda 09-050, 11-035, and 13-
016 and IRB protocol number HB-00050924-2.
2.1. Bacterial isolates
A. baumannii, K. pneumoniae, P. aeruginosa, E. coli, and MRSA isolates
from medical treatment facilities were grown on blood agar plates
(Difco, Detroit, MI, USA) for individual colonies. MDRO classiﬁcation
was based on previously published methods (Magiorakos et al., 2012).
Isolates were collected from 2002 to 2014 from hospital laboratories
across the United States, including Alaska and Hawaii, as well as Europe,
Central and South America, Asia and the Middle East; they came from
various anatomical sites, clinical settings (intensive care unit, ward, and
outpatient clinics), and patient population representing both genders
and all ages. Before submission to the central network laboratory where
this study was conducted, isolates were characterized by the accredited
laboratory of the submitting hospital (Waterman et al., 2012).
2.2. Strain evaluation
At the central laboratory, all isolates undergo concurrent testing on
the 3 AST platforms according to CLSI guidelines and CAP standards as
previously described (Lesho et al., 2014). Characterization by pulsed-
ﬁeld gel electrophoresis, multilocus sequence typing, PCR, and whole
genome sequencing (WGS) are performed as described previously
(Lesho et al., 2014; McGann et al., 2014). Suspected isolates carrying a
carbapenemase gene were conﬁrmed by the Carba NP assay, Real
Time-Polymerase Chain Reaction (RT-PCR), or WGS (Lesho et al.,
2013; McGann et al., 2013; Milillo et al., 2013). A large number (N300)
of distinct clades of A. baumannii, K. pneumoniae, P. aeruginosa, E. coli,
and MRSA were included (data not shown).
2.3. Identiﬁcation and antibiotic susceptibility testing
The following were used as controls: ATCC strain K. pneumoniae
700603, E. coli 35218 and 25922, P. aeruginosa 27853, Proteus vulgaris
49132, and Providencia stuartii 49809. Before testing, all analyzer panels
were prevalidated according to CAP guidelines. All platforms were si-
multaneously inoculated from a single culture plate and analyzed
using Phoenix panels NC44 or NC47 (Siemens, Deerﬁeld, IL, USA),
Vitek-2 cards GN30, GN59, or GN ID (bioMerieux, Durham, NC, USA),
and MicroScanWalk Away panels NMIC/ID133 (BD Diagnostics). Tech-
nicians rotated between the AST analyzers to mitigate operator bias.
RawMIC results were converted to their respective sensitive (S), in-
termediate (I), and resistant (R) categorical calls according to 2014 CLSI
guidelines using a Perl script (CLSI, 2014). Only antibiotics reported by
all platforms were considered. When derived categorical calls differed,
these disagreements were classiﬁed into 3 groups: a minor discrepancy
(mD) is an I call from 1 analyzer contrasted against 2 S or R calls from
the other platforms; a major discrepancy (MD) is an R call contrasted
against 2 S calls; and a very major discrepancy (VMD) is an S call
contrasted against 2 R calls.
Analogous to the minor, major, and very major error lexicon, we
used the term discrepancy for this comparison study as it is not feasible
to determine the MIC on such a large number of organism–antibiotic
combinations using manual broth or agar dilution methods. Hence,
the analyzer results themselves were used for discrepancy calls with
discrepancy types between instruments attributed to the platform
reporting the outlier categorical call. In rare cases where the derivedcalls were R, I, and S, theMIC values were determined based onmanual
microbroth dilutions (MBDs), per CLSI guidelines (CLSI, 2014), or the
Sensititer AIM and Trek (Thermo Fisher Scientiﬁc, Waltham, MA, USA)
system using plate GN2F. Controls for manual MBDs included at least
2 isolates from each species, one being sensitive and the other, resistant.
When discordant organism identiﬁcation was seen, the isolate was
retested on each platform, and ﬁnal adjudications were based on
MALDI-TOF, 16S sequencing, or WGS as previously described
(Carbonnelle et al., 2011; Center for Disease Control, 2013b). In addition
to the reference standards described above, we could also refer to the ID
and AST results of the submitting hospital laboratory (also CAP
accredited) for further adjudication.
All statistics were calculated using Fisher's exact (P b 0.05) or Yate's
χ2 tests using the R software package (R Developmental Core Team,
2010). A P-value of less than 0.01 or 0.05 was considered signiﬁcant
for data analyzed by the Yate's χ2 test or Fisher's exact, respectively.
3. Results
3.1. Organism identiﬁcation
Organism identiﬁcations among the 3 platforms agreed at the spe-
cies level for more than 99% of the 11,020 samples tested. MicroScan
and the Phoenix misidentiﬁed 52 out of 11,149 organism identiﬁed,
while the Vitek-2 misidentiﬁed only 5 (Table 1).
MicroScan misidentiﬁed A. baumannii signiﬁcantly more often than
Vitek-2 or Phoenix (P b 0.001, Yate's corrected χ2), mainly due to
reporting Shigella species in 16 of 1363 (1.2%) of cases. Vendor contacts
were unable to either resolve or explain this occurrence. Likewise, Phoe-
nix misidentiﬁed signiﬁcantly more A. baumannii than did Vitek-2 but
did not favor misidentiﬁcation of any one genus The Phoenix and
MicroScan instruments misidentiﬁed 9 isolates of P. aeruginosa. Overall
misidentiﬁcation of E. coli and K. pneumoniae were less than 2% on any
platform. MRSAwas the least likely to bemisidentiﬁed by any platform,
but when discrepancies occurred, they were identiﬁed as other Staphy-
lococcus species. In all cases of discrepant identiﬁcations, MALDI-TOF,
sequencing, and/or results of the submitting laboratory agreed with
themajority decision, further supporting our conclusion that the outlier
instrument is incorrect. Overall, Vitek-2 has the highest identiﬁcation
accuracy rate among all MDROs tested.
3.2. Antimicrobial susceptibility
Conﬂicting AST results among platforms were classiﬁed into mD,
MD, or VMD (deﬁned in Methods). Consistent with other reports, re-
gardless of organism or drug, all instruments produced a signiﬁcantly
higher proportion of mDs than any other type (data not shown)
(Kiyosuke et al., 2010; Markelz et al., 2012; Rybak et al., 2013). Overall,
MicroScan had the highest number of discrepancies due to frequently
reporting a 2-fold higher MIC yielding a categorical call of I or R relative
to S or I on the other platforms, respectively. Full antibiograms or organ-
isms with their respective RIS combinations can be found as supple-
mental ﬁles.
3.3. Gram-negative organisms
Occurrences of MD and VMD for A. baumannii, K. pneumoniae, P.
aeruginosa, and E. coliMDRO isolates were summed (Table S1) and tal-
lied by speciﬁc organism and drug (Table 2). All instrument/drug/or-
ganism combinations performed at or better than the manufacturer's
speciﬁed error rate with exception to 2 notable combinations. The ﬁrst
exception was E. coli tested on the MicroScan against azteronam,
which resulted in 101/1322 isolates reporting an MIC corresponding
to resistance compared to a sensitive MIC interpretation on the other
platforms (Table 2). To ensure the discrepancy rate was above 5%, sam-
ples were repeated, and an overall error rate of 7.95% was calculated.
Table 1
Identiﬁcation discrepancies among the MicroScan, Phoenix, and Vitek-2 platforms.
Adjudicated identiﬁcation No. of isolatesa MicroScan Phoenix Vitek-2
A. baumannii 1363 Empedobacter (F.) brevis (1b) Acinetobacter lwofﬁi/haemolyticus (1) Pseudomonas stutzeri (1)
Acinetobacter lwofﬁi (4) Burkholderia cepacia (2)
E. coli (1) K. pneumoniae (1)
Leminorella (2) Pantoea agglomerans (2)
Proteus oryzihabitans (1) Alcaligenes faecalis (2)
Shigella (16) Cupriavidus pauculus (1)
B. cepacia (1) D. acidovorans (1)
E. coli 2091 Kluyvera ascorbata (7) C. freundii (4)
A. lwofﬁi (1) P. agglomerans (1)
Citrobacter amalonaticus (1) Enterobacter cloacae (2)
Vibrio vulniﬁcus (1) S. choleraesuis ssp. arizonae (2)
K. ascorbata (4)
K. pneumoniae 568 Enterobacter aerogenes (3) E. aerogenes (5) Klebsiella oxytoca (1)
K. oxytoca (4) E. cloacae (3)
Serratia odorifera (1) K. oxytoca (2)
Enterobacter sakazakii (1)
P. aeruginosa (1)
P. aeruginosa 711 E. coli (1) Pseudomonas genus (5) E. cloacae complex (1)
Pseudomonas ﬂuorescens (3) E. coli (1) P. ﬂuorescens (1)
A. baumannii (1) P. ﬂuorescens (1) Pseudomonas putida (1)
P. stutzeri (1) Staphylococcus hyicus (2)
P. oryzihabitans (3)
MRSA 6416 Staphylococcus intermedius (1) S. intermedius (1)
Staphylococcus xylosus (1) Staphylococcus genus (7)
a Total isolates compared, including those with discrepant identiﬁcations.
b Count of occurrence.
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platforms for most of the organism/drug combinations with exception
of nitrofurantoin/E. coli on the Vitek-2 and ciproﬂoxacin/P. aeruginosaTable 2
Occurrence of VMD and MD in select Gram-negative MDROs.
E. coli
Na MD VMD
Group Abx Mb P V M
β-Lactam SAM 2071 15c 11 1 6
Penicillin AMP 2072 7 5 0 1
Monobactam ATM 855 68 0 0 0
Cephalosporins CFZ 1554 0 0 0 0
CAZ 740 13 3 0 0
CRO 1219 0 0 0 0
Carbapenems ERT 1635 30 0 0 0
IMP 1521 15 0 0 0
Aminoglycosides AMK 2071 18 0 0 0
GEN 2071 35 7 0 2
TOB 2071 22 10 0 1
Fluoroquinolones CIP 1715 24 2 0 0
LVX 741 30 0 0 0
Nitrofuran NIT 1795 18 5 21 1
Folate Inhibitor SXT 2068 40 16 5 13
P. aeruginosa
N MD VMD
Group Abx M P V M
Monobactam ATM 2 0 0 1 0
Cephalosporins CAZ 314 4 3 2 0
CRO - - - - -
Carbapenems IMP 532 3 5 0 2
Aminoglycosides AMK 676 15 2 6 1
GEN 676 13 8 1 1
TOB 674 15 9 2 2
Fluoroquinolones CIP 546 2 10 1 0
LVX 314 6 2 3 1
Abx = antibiotic; AMK = amikacin; SAM = ampicillin/sulbactam; AMP = ampicillin
CIP = ciproﬂoxacin; ERT = ertapenem; GEN = gentamicin; IMP = imipenem; LVX = levoﬂo
a Total number of isolates reported.
b Commercial platform: M, MicroScan; P, Phoenix; V, Vitek-2.
c Gray shading indicates that there is a signiﬁcant difference among the 3 analyzers based o
d Dash represents no data.on the Phoenix. However, all other combinations resulting in an MD
corresponded to less than a 5% discrepancy rate to the total number of
isolates tested for a particular instrument/drug/organism combination.K. pneumoniae
N MD VMD
P V M P V M P V
0 18 547 3 7 0 2 0 3
1 1 547 2 0 0 0 0 0
7 41 300 5 0 0 0 9 1
0 0 464 0 0 0 0 0 0
1 21 206 0 0 0 0 1 2
0 5 425 0 0 0 0 0 0
0 2 140 9 0 0 0 0 1
0 0 383 5 5 3 8 6 0
3 1 547 6 0 1 0 0 1
1 4 547 10 2 0 2 0 2
1 5 547 3 0 0 0 0 1
1 0 488 4 2 0 2 0 8
0 0 206 3 0 0 0 0 0
0 0 393 0 1 2 4 0 0
7 7 546 12 4 0 1 7 11
A. baumannii
N MD VMD
P V M P V M P V
0 0 -d - - - - - -
2 2 982 8 0 1 0 0 1
- - 1323 0 0 0 2 0 2
7 3 11 1 0 0 0 0 1
9 2 1 0 0 0 0 0 0
3 3 1322 22 2 0 1 1 11
1 3 1322 47 3 0 1 0 101
2 9 1062 13 0 0 0 0 0
3 0 981 6 0 0 0 0 0
; ATM = azteronam; CFZ = cefazolin; CAZ = ceftazidime; CRO = ceftriaxone;
xacin; NIT = nitrofuratoin; TOB = tobramycin; SXT = trimethoprim/sulfamethoxazole.
n a 3 × 2 Yate's χ2 correction P b 0.01.
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tobramycin. Of 1322 isolates tested on the Vitek-2, 101 (7.6%) reported
anMIC of 4 μg/mL or less relative to the other platforms, which reported
anMIC of 16 μg/mL or greater. This high VMD error rate was not seen in
other drug/organism/platform combinations. Fewer VMDs were noted
than MD for all instruments, and no combination gave a more than a
5% isolate testing error rate. However, signiﬁcant differences between
similar drug/organism combinations ran on different platforms oc-
curred. Speciﬁcally, Vitek-2 reported a higher proportion of VMD with
E. coli against sulbactam/ampicillin, azteronam, ceftazidime, and ceftri-
axone relative to the either the Phoenix or MicroScan. For K.
pneumoniae, more VMDs were noted on the Phoenix and azteronam,
the MicroScan and imipenem, and the Vitek-2 and ciproﬂoxacin or
trimethoprim/sulfamethoxazole than other instrument/drug combina-
tions. The only notable signiﬁcant difference among P. aeruginosa
VMD occurrences was found when testing amikacin on the Phoenix. A.
baumannii testing revealed 2 drug/instrument combinations that gave
higher VMD rates compared to the other platforms: gentamycin and
tobramycin on the Vitek-2.
Cefepime was associated with the highest percentage of both MDs
and VMDs on the MicroScan and Vitek-2 platforms, respectively, than
any other drug/organism combination (Table S2). Many more discrep-
ant results were seen for E. coli and K. pneumoniae than for P. aeruginosa
or A. baumannii (data not shown). The MIC values of several isolates
tested prior to the cefepimebreakpoint change (CLSI, 2014) did not pro-
vide sufﬁcient granularity to assign categorical calls. Therefore, cefe-
pime was analyzed separately from other antibiotics by using raw
MICs for comparison (Table 3). Most often, MicroScan and Phoenix re-
ported the same MIC values for all organisms, and Vitek-2 was the out-
lier, reporting anMIC 2–6 dilutions lower. Subsets of these isolates were
tested byMBD. TheMIC values determined by this method agreed with
those reported by MicroScan and Phoenix if the MIC was greater than
16. This suggests the Vitek-2 often underestimated the MIC values of
E. coli and K. pneumoniae (Table 3).
To understand how the CLSI breakpoint affected our data, we com-
pared our cefepime data using 2013 and 2014 CLSI guidelines. Based
on the 2013 CLSI guidelines, we found Vitek-2 reported 44% of E. coli
and 35% of K. pneumoniae isolates to be susceptible to cefepime when
both the Phoenix and MicroScan reported resistance. Analysis of the
data that could be interpreted using the updated 2014 CLSI standards
decreased the rate of E. coli VMD reported by Vitek-2 to 23% and K.
pneumoniae isolates to 27% VMD (Table S2). The proportions of MDs at-
tributed to theMicroScan also changed. Based on 2013 guidelines, E. coli
and K. pneumoniae resulted in a 16% and 6%, respectively, MIC overesti-
mation compared to the other platforms. However, reanalysis using the
2014 guidelines found a reduction of MicroScan MD rate to 10% for E.
coli isolates but an increase to 15% for K. pneumoniae isolates. However,
the number of isolates interpreted across all platforms using the 2013
versus 2014 guidelines showed an improvement in categorical callTable 3
Common cefepime MIC patterns across AST platforms and MBD results in this study.
MIC value
Organism MicroScan Phoenix Vitek-2 Occurrences MBD MIC (n)a
E. coli N16 ≤1 ≤1 20 0.5 (3)
N16 8 2 46 16 (4), 8 (1)
N16 N16 2 207 32 (1)
N16 N16 4 124 32 (5)
N16 N16 8 156 32 (2)
K. pneumoniae N16 N16 2 87 32 (2)
A. baumannii 16 8 32 8 16 (2)
N16 8 ≥64 5 32 (1)
16 8 ≥64 7 16 (2)
P. aeruginosa ≤8 N16 ≥64 2 32 (1)
≤8 N16 2 2 4 (1)
a MIC results of MBD by either manual or Trek Sensititer. The number in parentheses
denotes the number of subset isolates tested resulting in the given MIC value.agreement across all platforms including an increase of 26–29% of E.
coli categorical calls and 36–43% of K. pneumoniae isolates.
3.4. Carbapenemase producers
Carbapenemase production was conﬁrmed using the Carba NP test
(Tijet et al., 2013), and the molecular mechanism was determined by
real-time PCR or WGS. Carba NP–positive isolates contained blaNDM-1,
blaIMP, blaKPC, blaOXA-48, or blaVIM. No signiﬁcant difference between
the numbers of discrepancies produced by any platform/drug combina-
tion was found in A. baumannii isolates producing an NDM-1 (n = 21)
or IMP (n = 3) metallo-β-carbapenemase relative to non–
carbapenemase-producing A. baumannii samples. In KPC-producing E.
coli andK. pneumoniae isolates (n=10 and91, respectively), higher dis-
crepancy rates compared to noncarbapenemase gene carriers were only
seen for cefepime tested on Vitek-2 and imipenem assayed on Phoenix
(Table 2). For cefepime, 9/10 E. coliKPC-positive organisms and 22/91K.
pneumoniae isolates were reported as susceptible (MIC = 2 μg/mL) on
the Vitek-2, while an MIC N16 μg/mL was reported by the MicroScan
and Phoenix. As observed with non-KPC isolates, the Vitek-2
underestimated cefepime MIC values; however, inaccurate reports
were more common and signiﬁcant in those isolates producing a KPC
carbapenemase (E. coli P b 0.001, K. pneumoniae P = 0.037, Fisher's
exact test). Imipenem susceptibility was erroneously reported by the
Phoenix platform in 4/10 E. coli and 10/91 K. pneumoniae KPC-carrying
isolates, whereas in non-KPC producers, no discrepancies were found
in a sample size of 510 and 133, respectively. Enterobacteriaceae carry-
ing the blaNDM-1 or blaOXA-48 genes produced similar discrepancy rates
to noncarbapenemase producers. Two P. aeruginosa isolates, one pro-
ducing a KPC and the other a VIM type carbapenemase, had consistent
MIC values across all platforms and drugs tested.
3.5. MRSA
NoMRSA testing combinations resulted in a greater than 5% discrep-
ancy rate (Table 4). Most errors weremDs andwere drug, not platform,
dependent. No conﬁrmatory testing of mDs was performed. For MDs,
MicroScan and Phoenix were statistically signiﬁcantly more likely than
the Vitek-2 to show discrepancies for tetracycline and vancomycin.
MicroScan reported a greater proportion of MDs for rifampicin,
moxiﬂoxacin, levoﬂoxacin, erythromycin, and clindamycin than the
other platforms. Vitek-2 had a signiﬁcantly higher MD rate reported
for daptomycin testing than the other 2 instruments (Table 4). Errone-
ous reporting of vancomycin resistance by automated platforms has
been previously reported (Rybak et al., 2013). When this occurred, iso-
lates were retested and/or interrogated with PCR or WGS for resistance
genes. There were no conﬁrmed instances of vancomycin resistance.
Few VMDs were found for MRSA isolates on any platform.
4. Discussion
Inwhat is the largest reported comparison to date, we tested the an-
tibiotic susceptibilities and identiﬁcations of 11,020 and 11,149 MDRO
isolates, respectively, from the same culture plate on the Phoenix,
MicroScan, and Vitek-2 platforms yielding a total of 418,521 data points
for analysis. All platforms often agreed on assigning correct organism
identiﬁcation more than 99% of the time, with the Vitek-2 reporting
the least identiﬁcation discrepancies. For antibiotic susceptibility test-
ing, we found all analyzers performed according to manufacturer's
speciﬁcations for most antibiotic and organism combinations. Notable
exceptions included cefepime and tobramycin. Using the 2014 CLSI
breakpoints, cefepime sensitivity was overreported by the Vitek-2 for
ESBL-positive E. coli and K. pneumoniae. Often, these MICs were 2- to
3-fold lower MIC values than reported by the other platforms leading
to a high VMD rate (data not shown). Lower MICs were also reported
by the MicroScan than MBD testing. Neither VMD nor MD errors were
Table 4
MRSA discrepancy rates.
Discrepancy
typea Platform CLIb DAP ERY LEV LZD MOX PEN RIF TET VAN
mD MicroScan 92 0 62 57 0 413 0 30 33 17
Phoenix 3 0 47 30 0 234 0 0 21 1
Vitek–2 6 0 84 81 0 392 0 3 8 1
M D MicroScan 78 15 43 159 21 138 3 33 34 24
Phoenix 12 13 10 4 5 3 4 1 20 21
Vitek–2 3 245 1 2 12 3 1 0 4 4
VMD MicroScan 4 2 8 5 0 4 32 6 0 0
Phoenix 5 6 2 10 2 14 1 0 1 0
Vitek–2 9 0 13 4 0 3 6 0 6 0
No discrepancy 6182 6112 6127 6033 6360 5185 3966 6315 6258 6330
N isolates 6398 6393 6399 6393 6400 6399 4013 6399 6398 6399
CLI = clindamycin; DAP = daptomycin; ERY = erythomycin; LEV = levoﬂoxacin; LZD = linezolid; MOX = moxiﬂoxacin; PEN = penicillin; RIF = rifampicin; TET = tetracycline;
VAN = vancomycin.
aDiscrepancy type: mD, MD, and VMD.
bShading indicates signiﬁcant difference between same discrepancy type relative to other platforms at P b 0.01, Yate's corrected χ2.
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timeframe, suggesting that this ﬁnding is an ongoing occurrence.
Vendor inquiry did not resolve our ﬁndings.
A high number ofA. baumannii isolates tested against tobramycinwere
reported as sensitive by theVitek-2 and resistant by the other instruments.
Samples were reran and conﬁrmed to produce the same categorical call,
although theMIC of individual isolatesmay have alteredwithin 1 dilution.
This result was exclusive to A. baumannii isolates, as MICs from the other
tested organisms compared exceptionally well across all instruments.
We have been unable to ﬁnd similar literature reports suggesting that
further investigation to determine if this is a common outcome of
multidrug-resistant A. baumannii isolates or common to all is warranted.
Our study is the ﬁrst to provide such comparisons without the need
for multiple subcultures, testing centers, and days between testing of
samples on each platform as all inoculum came from the same plate
under the same growth conditions. It is also one of the ﬁrst to use the
newest 2014 CLSI breakpoints. Finally, it includes a large, genetically
diverse collection of samples and the most number AST result
comparisons of conﬁrmed carbapenemase producers to date.
Thaden et al. (2014) found that hospitals using the Vitek-2 had
signiﬁcantly higher rates of carbapenem-resistant Enterobacteriaceae
detection compared to those using MicroScan, but the Phoenix was
not included in that study (Bobenchik et al., 2014). We found that the
ability of an isolate to produce a carbapenemase did not result in more
AST discrepancies than did those noncarbapenemase producers, with
the exception of blaKPC-containing Enterobacteriaceae and cefepime
on the Vitek-2 and imipenem on the Phoenix platform.
For cefepime results, we suggest using another validation method if
clinically important, especially if reported as susceptible by Vitek-2. No
susceptible isolates were reported resistant to imipenem on the Phoe-
nix, suggesting that the Phoenix reports false negatives, but not false
positives. Interestingly, higher discrepancy rates in both Vitek-2/
cefepime and Phoenix/imipenem combinations occurred only in En-
terobacteriaceae containing a kpc gene.Woodford et al. (2010) conclud-
ed that blaOXA-48–containing organisms were poorly detected on any of
the 3 AST platforms, while KPC producers and other metallo-β-
carbapenemases were accurately detected. Using a genetically diverse
and larger sample size, our study is consistent with this conclusion for
blaNMD-1–, blaIMP-, and blaVIM-containing organisms but does not sup-
port the poor detection of blaOXA-48–containing isolates or the robust
detection of KPC producers.Gram-positive agreement/performance was worse than for
Gram negatives, as several MD categorical discrepancies were
detected. Overall, MicroScan reported MICs that were 2- to 4-fold
higher than those reported by either the Vitek-2 or Phoenix. Most
concerning is in the case of the quinolones levoﬂoxacin and
moxiﬂoxacin. We did not accrue enough data to report on other
quinolones, including ciproﬂoxacin and gatiﬂoxacin, to determine
if this outcomewas speciﬁc to these drugs or the entire drug family.
For vancomycin, all platforms were previously noted to report false
positives, although this was seen more often on the Vitek-2 (Rybak
et al., 2013). In our study, we found a higher false-positive rate
using the MicroScan platform, although discrepancies still existed
on the Vitek-2 and Phoenix suggesting that they produce the
least number of false-positive discrepancies when reporting
MRSA vancomycin results. Since laboratories are especially con-
cerned with vancomycin-resistant MRSA, erroneous resistance re-
ports increase workload and could needlessly eliminate an
effective antibiotic.
In addition to accuracy, cost and throughput are relevant consider-
ations. Various analyzer panels (ID and AST or AST only), contracting
agreements, and pricing structures hamper cost comparisons. If only
AST panels are used, Vitek-2 processes the most isolates per run (120)
but the least (60) if also determining identiﬁcation. The Phoenix and
MicroScan process 98 sample per run, supplying both ID and AST re-
sults. For us, the MicroScan has the lowest cost per isolate and per
panel. Vitek-2 and Phoenix were 1.54 and 1.68 times the cost of
MicroScan, respectively.
Our study has important limitations. First, it was not ﬁnancially or
logistically feasible to perform manual broth dilution on all the isolates
due to the prohibitively large number of isolate–antibiotic combina-
tions. Second,we focused ononly a few species or genera known to con-
stitute the most problematic nosocomial pathogens. Third, only MDRO
isolates were included. While these are not expected to perform differ-
ently for ID and AST testing than non-MDRO isolates, this possibility
cannot be excluded.
In summary, these data from a large, same plate and day comparison
of the 3 most utilized automated platforms suggest that while all plat-
forms performed in overall accordance with themanufacturers' speciﬁ-
cations, each had notable strengths and weaknesses for organism
identiﬁcation, speciﬁc drug–organism combinations, and inferring
carbapenemase production.
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